Correction for Schneweis et al., Stroke 32 (8) 1863-1867.
Correction for Lees et al., Stroke 32 (2) 466-472.

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Search for Related Content

(Stroke. 2001;32:2961.)
© 2001 American Heart Association, Inc.

In "Tolerability of the Low-Affinity, Use-Dependent NMDA Antagonist AR-R15896AR in Stroke Patients: A Dose-Ranging Study," by Lees et al, an error in the wording of a paragraph in the Results section was introduced during a revision of the manuscript. The paragraph (on page 470) should read as follows:

Stroke Outcome The numbers of patients achieving good outcome, as defined by 1-month Barthel score 95 to 100, 1-month modified Rankin scale of 0 to 1, or 1-week NIHSS 0 to 1, were 42, 39, and 25, respectively, for AR-R15896AR versus 22, 23, and 12 with placebo. Moderate outcome, as defined as Barthel score 60 to 90, modified Rankin scale 2 to 3, or NIHSS 2 to 8, was achieved in 24, 20, and 45 patients with AR-R15896AR and 12, 8, and 23, respectively, after placebo. There was no statistically significant difference between placebo and active groups with regard to any outcome.

The author of a recent editorial comment, "Investigating Acute Stroke: Does Invasive Monitoring Add to Identifying Patients at Risk for Progression?" was incorrectly identified.

The guest editor of the comment was Ashfaq Shuaib, MD.

Footnotes

[Correction for Vol 32, Number 2, February 2001. Pages 466–472.]

[Correction for Vol 32, Number 8, August 2001. Pages 1866–1867.]